Julie L. Eiseman
- Molecular Biology top 5%
- Cancer therapeutics and mechanisms 27
- Epigenetics and DNA Methylation 9
- Oncology top 5%
- Cancer Treatment and Pharmacology 16
- Drug Transport and Resistance Mechanisms 11
- Biomaterials top 5%
- Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism 10
- Toxicology top 2%
-
- Cancer, Hypoxia, and Metabolism 10
-
- Cancer Research and Treatments 8
-
- Nanoplatforms for cancer theranostics 7
- Co-authors
- Merrill J. EgorinErin JosephJoseph M. CoveyRobert A. PariseDorothy L. SentzAlvito P. AlvaresJan H. BeumerDeborah R. Hamburger
- Partner nations
- United StatesCanadaNetherlands
In The Last Decade
Julie L. Eiseman
130 papers receiving 3.4k citations
Peers
Comparison fields: 5 of 125
- Molecular Biology 2.1k
- Oncology 733
- Biomaterials 344
- Pharmacology 195
- Toxicology 74
Countries citing papers authored by Julie L. Eiseman
This map shows the geographic impact of Julie L. Eiseman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie L. Eiseman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie L. Eiseman more than expected).
Fields of papers citing papers by Julie L. Eiseman
This network shows the impact of papers produced by Julie L. Eiseman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie L. Eiseman. The network helps show where Julie L. Eiseman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Julie L. Eiseman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 42 | |
| 2 | 2016 | 18 | |
| 3 | 2016 | 9 | |
| 4 | 2015 | 2 | |
| 5 | 2014 | 5 | |
| 6 | 2013 | 6 | |
| 7 | 2012 | 23 | |
| 8 | 2012 | 4 | |
| 9 | 2010 | 12 | |
| 10 | 2010 | 23 | |
| 11 | 2007 | 10 | |
| 12 | 2007 | 9 | |
| 13 | A physiologically-based pharmacokinetic (PBPK) model of docetaxel in SCID mice bearing SKOV3 human ovarian cancer xenografts | 2006 | 1 |
| 14 | Plasma, tissue and tumor disposition of STEALTH® liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenografts | 2006 | 3 |
| 15 | 1999 | 25 | |
| 16 | 1994 | 13 | |
| 17 | 1993 | 13 | |
| 18 | 1991 | 40 | |
| 19 | Physical growth and endocrine correlates of blood pressure variation among bundi gende speaking adolescents of papua new guinea | 1990 | 2 |
| 20 | 1978 | 26 |
About Julie L. Eiseman
Julie L. Eiseman is a scholar working on Oncology, Pharmacology and Cancer Research, having authored 131 papers that have together received 3.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (27 papers), Cancer Treatment and Pharmacology (16 papers), Drug Transport and Resistance Mechanisms (11 papers), Pharmacogenetics and Drug Metabolism (10 papers), Cancer, Hypoxia, and Metabolism (10 papers), Epigenetics and DNA Methylation (9 papers), Cancer Research and Treatments (8 papers) and Nanoplatforms for cancer theranostics (7 papers). The work is most often cited by research in Molecular Biology (2.1k citations), Oncology (733 citations) and Biomaterials (344 citations). Julie L. Eiseman has collaborated with scholars based in United States, Canada and Netherlands. Frequent co-authors include Merrill J. Egorin, Erin Joseph, Joseph M. Covey, Robert A. Parise, Dorothy L. Sentz, Alvito P. Alvares, Jan H. Beumer, Deborah R. Hamburger, Donald J. Creighton and Jianxia Guo. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.